Aadi Bioscience Rockets 72% on Key Updates

Seeking AlphaDec 20 15:37

KAKEN PHARMACEUTICAL To Go Ex-Dividend On March 28th, 2025 With 0.66 USD Dividend Per Share

November 8th (Eastern Time) - $KAKEN PHARMACEUTICAL(KKPCF.US)$ is trading ex-dividend on March 28th, 2025.Shareholders of record on March 31st, 2025 will receive 0.66 USD dividend per share on June 30

Futu NewsNov 9 08:45

KAKEN PHARMACEUTICAL To Go Ex-Dividend On September 27th, 2024 With 0.66 USD Dividend Per Share And 0.352 USD Special Dividend Per Share

July 9th (Eastern Time) - $KAKEN PHARMACEUTICAL(KKPCF.US)$ is trading ex-dividend on September 27th, 2024.Shareholders of record on September 30th, 2024 will receive 0.66 USD dividend per share on

Futu NewsJul 10 07:40

Kaken Pharmaceutical Sees FY Net Y5.60B

Dow JonesMay 14 12:30

Kaken Pharmaceutical FY Net Y8.03B Vs Net Y5.44B

Dow JonesMay 14 12:30

Transfer of the rights of “Melislon” and “Mionar” in Japan to Kinkaku Pharmaceutical

For printing 2024/3/29, Eisai Co., Ltd. (Headquarters: Tokyo; Representative Executive Officer and CEO: Haruo Naito) is pleased to announce that it has now signed an agreement to transfer domestic rights to the vertigo and balance disorder treatment agent “Melisone” (generic name: betahistine mesylate) and the muscle tone improving agent “Mional” (generic name: eperisone hydrochloride) to Kagaku Pharmaceutical Co., Ltd. (Headquarters: Tokyo, hereinafter referred to as Kaken Pharmaceutical). “Merislon” and “Mionard” are those in Japan

EisaiMar 28 23:00